DelveInsight’s Metastatic Colorectal Cancer pipeline report depicts a robust space with 150+ active players working to develop 180+ pipeline therapies for Metastatic Colorectal Cancer treatment.

The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic ...

Metastatic Colorectal Cancer companies working in the treatment market are Plus Therapeutics, Processa Pharmaceuticals, Shanghai Henlius Biotech, Genor Biopharma, Novartis Pharmaceutical, Sumitomo ...

The US Food and Drug Administration (FDA) has approved Anbogen Therapeutics’ investigational new drug (IND) application for ...

Anbogen Therapeutics gains FDA approval for ABT-301, initiating a pivotal trial for metastatic colorectal cancer, targeting ...

Metastatic Colorectal Cancer Pipeline constitutes 80+ key companies continuously working towards developing 100+ Metastatic Colorectal Cancer treatment therapies, analyzes DelveInsight.

In addition to these treatment, the metastatic colorectal cancer market is witnessing a growing focus on combination therapies, where multiple drugs from different classes are used in tandem to ...

Key Takeaways Leronlimab demonstrated partial or complete responses in advanced metastatic colorectal cancer, supporting its potential in solid tumor oncology. Increased PD-L1 expression in ...

The treatment paradigm for mCRC involves multiple lines of therapy. First-line (1L) metastatic colorectal cancer treatments include combination chemotherapy regimens such as FOLFOX, FOLFIRI, and ...